Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

• Market Cap: ¥33.95B
• Dividend Yield: 6.29%
• Average Volume (3M): 64.11K
• Price to Earnings (P/E): 12.1
• Beta (1Y): 0.37
• Revenue Growth: -12.03%
• EPS Growth: -19.61%
• Country: JP
• Employees: 187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 29.82
• Shares Outstanding: 19,051,200
• 10 Day Avg. Volume: 72,640
• 30 Day Avg. Volume: 64,113
• PEG Ratio: -250.24
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 2.50
• P/FCF Ratio: 9.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 85 Outperform
• Price Target: ¥2,026.00 ▲(15.57% Upside)

The score is driven primarily by strong financial quality (high margins, solid free cash flow, and zero debt). Technicals are supportive with an established uptrend, but near-overbought RSI tempers the technical component. Valuation is favorable with a modest P/E and a high dividend yield.

Positive Factors

Profitability

High profitability margins indicate efficient operations and strong pricing power, supporting sustainable earnings and competitive positioning.

Balance Sheet Health

Zero debt enhances financial stability, reduces risk, and provides flexibility for future investments or weathering economic downturns.

Cash Generation

Strong cash generation supports ongoing operations, potential dividends, and reinvestment opportunities, ensuring long-term business viability.

Negative Factors

Revenue Growth Volatility

Inconsistent revenue growth can challenge strategic planning and investor confidence, impacting long-term growth prospects.

Earnings Volatility

Earnings volatility can complicate forecasting and investment decisions, potentially affecting market perception and valuation stability.

Cash Flow Volatility

Volatile cash flow can hinder consistent capital allocation and strategic investments, affecting long-term operational and financial planning.

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen test kits; pregnancy test kits; ovulation test kits; and fecal occult blood test kits. It also offers gene analysis instrument; SARS-CoV-2 detection kits; and mycoplasma pneumoniae nucleic acid kits. In addition, the company engages in import and export activities. It also operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, etc. The company was incorporated in 1977 and is headquartered in Tosu, Japan.

How the Company Makes Money

Mizuho Medy Co., Ltd. generates revenue through the sale of its medical devices and healthcare products. The company targets hospitals, clinics, and other healthcare facilities as its primary customer base, supplying them with essential medical equipment and consumables. Revenue is driven by the continuous demand for high-quality and reliable medical devices, which are crucial for patient care and medical procedures. The company may also engage in partnerships or collaborations with other healthcare organizations to expand its product offerings and reach a wider market. Additionally, Mizuho Medy Co., Ltd. may benefit from ongoing advancements in medical technology, which can lead to the development of new products and open up additional revenue streams.

Mizuho Medy Co., Ltd. Financial Statement Overview

Summary

Overall financials are strong, supported by high profitability (2024 gross margin ~71%, operating margin ~43%, net margin ~33%), solid free cash flow generation with strong cash conversion (~91% of net income in 2024), and an exceptionally conservative balance sheet (zero debt in 2021–2024). The main constraint is volatility/normalization versus the 2022 peak and uneven growth.

Income Statement

Profitability is strong in the most recent year (2024) with high gross margin (~71%) and robust operating and net margins (~43% and ~33%). Revenue growth re-accelerated in 2024 (+4.0%) after a slight decline in 2023, but results remain well below the 2022 peak—2022 shows unusually high margins and earnings versus 2023–2024, suggesting a step-down in the earnings base and some volatility in the growth trajectory. Overall, the company screens as highly profitable, but with notable year-to-year swings since 2022.

Balance Sheet

The balance sheet is exceptionally conservative: total debt is reported at zero from 2021 through 2024, driving a debt-to-equity ratio of 0.0 and materially reducing financial risk. Equity has grown meaningfully over time, and returns on equity remain healthy in 2023–2024 (~24% and ~22%), though down sharply from the very elevated levels in 2021–2022. Main drawback is that profitability (and therefore return on equity) has normalized from prior peaks, but leverage risk is minimal.

Cash Flow

Cash generation is solid: operating cash flow and free cash flow are positive and sizable in 2024 (about ¥3.35B and ¥3.05B). Cash earnings quality looks good, with free cash flow running at ~91% of net income in 2024 (and ~93–97% in 2021–2023). Operating cash flow also covers net income comfortably in 2021–2024 (well above 1x). Weaknesses include volatility in free cash flow growth (large spike in 2024 after a decline in 2023) and a weaker cash-flow profile in earlier years (including negative free cash flow in 2019 and low coverage in 2020), though the more recent period is clearly stronger.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.74B	11.43B	10.99B	17.58B	12.89B	4.20B
Gross Profit	7.63B	8.08B	8.07B	14.10B	9.65B	2.76B
EBITDA	4.71B	5.15B	5.35B	11.23B	7.00B	611.11M
Net Income	3.30B	3.77B	3.77B	7.84B	4.82B	306.35M
Balance Sheet
Total Assets	19.73B	20.73B	18.95B	19.10B	12.19B	6.05B
Cash, Cash Equivalents and Short-Term Investments	12.37B	11.25B	10.13B	8.70B	4.33B	54.31M
Total Debt	0.00	0.00	0.00	0.00	0.00	593.34M
Total Liabilities	2.50B	3.38B	3.27B	4.82B	4.16B	2.27B
Stockholders Equity	17.23B	17.35B	15.68B	14.28B	8.03B	3.78B
Cash Flow
Free Cash Flow	0.00	3.05B	3.72B	5.99B	5.44B	198.36M
Operating Cash Flow	0.00	3.35B	3.99B	6.17B	5.60B	295.42M
Investing Cash Flow	0.00	-307.00M	-270.45M	-1.55B	-159.74M	-97.32M
Financing Cash Flow	0.00	-2.09B	-2.38B	-1.57B	-1.16B	-361.10M

Mizuho Medy Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1753.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1753 is below the 20-day moving average (MA) of 1780.35, above the 50-day MA of 1687.50, and above the 200-day MA of 1527.69, indicating a bullish trend. The MACD of 25.55 indicates Positive momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 26.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	85 Outperform	¥33.95B	12.08	―	6.29%	-12.03%	-19.61%
4569	69 Neutral	¥85.28B	9.98	―	3.36%	11.65%	93.46%
4886	67 Neutral	¥66.48B	14.87	―	2.52%	5.44%	-20.33%
4577	63 Neutral	¥40.14B	17.94	―	2.75%	7.56%	-48.91%
4538	60 Neutral	¥19.93B	-4.86	―	3.71%	7.50%	-281.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%